Prion diseases, also known as transmissible spongiform encephalopathies, are a group of fatal neurodegenerative diseases that include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans. The ‘protein only hypothesis’ advocates that PrPSc, an abnormal isoform of the cellular protein PrPC, is the main and possibly sole component of prion infectious agents. Currently, no effective therapy exists for these diseases at the symptomatic phase for either humans or animals, though a number of compounds have demonstrated the ability to eliminate PrPSc in cell culture models. Of particular interest are synthetic polymers known as dendrimers which possess the unique ability to eliminate PrPSc in both an intracellular and in vitro setting. The efficacy and mode of action of the novel anti-prion dendrimer mPPIg5 was investigated through the creation of a number of innovative bio-assays based upon the scrapie cell assay. These assays were used to demonstrate that mPPIg5 is a highly effective anti-prion drug which acts, at least in part, through the inhibition of PrPC to PrPSc conversion. Understanding how a drug works is a vital component in maximising its performance. By establishing the efficacy and method of action of mPPIg5, this study will help determine which drugs are most likely to enhance this effect and also aid the design of dendrimers with anti-prion capabilities for the future.
Citation: McCarthy JM, Franke M, Resenberger UK, Waldron S, Simpson JC, Tatzelt J, et al. (2013) Anti-Prion Drug mPPIg5 Inhibits PrPC Conversion to PrPSc. PLoS ONE 8(1): e55282. https://doi.org/10.1371/journal.pone.0055282
Editor: Ina Maja Vorberg, Deutsches Zentrum für Neurodegenerative Erkrankungen e.V., Germany
Received: August 13, 2012; Accepted: December 29, 2012; Published: January 28, 2013
Copyright: © 2013 McCarthy et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funding from University College Dublin, the Irish Research Council for Science, Engineering & Technology (IRCSET) the European Union (Dendrimers in Biomedical Applications – COST TD0802, Neuroprion – FOOD-CT-2004-506579), the Irish Department of Agriculture, Food and Rural Development (FIRM 01-R&D-D-160), the Saxon Ministry for Science and Art and The German Ministry for Education and Science, as well as the DFG SFB 596 (to Jörg Tatzelt and Ulrike K. Resenberger). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist. For completeness, University College Dublin and Prof. Rogers receive royalties associated with the use of a BSE diagnostic test approved by the European Union. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Prion diseases are a group of fatal neurodegenerative diseases that can be genetic, infectious or sporadic in origin. They include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle, and Creutzfeldt-Jakob disease (CJD) in humans. The ‘protein only hypothesis’ advocates that PrPSc, a misfolded form of the endogenous prion protein, is the main and possibly sole component of prion infectious agents , . No effective therapy exists for prion diseases at the symptomatic phase for either humans or animals. However, several molecules including congo red , sulphated polyanions , cyclic tetrapyrroles (porphyrins and phthalocyanines) , branched polyamines , , suramin , STI571  and quinacrine  have demonstrated the ability to eliminate PrPSc in cell culture models. Synthetic macromolecules known as dendrimers are a particularly interesting class of anti-prion compounds as numerous dendrimer species possess the ability to eliminate PrPSc in both an intracellular and in vitro setting. Evidence suggests that this is achieved by interacting directly with PrPSc and rendering it sensitive to proteases , . Within the cell this is thought to occur within acidic endosomes or lysosomes  though recently it has been speculated that certain dendrimers may eliminate PrPSc by inhibiting the conversion of PrPC to PrPSc , .
In the present work, we examined the anti-prion efficacy of maltose modified poly(propylene imine) generation five dendrimers (mPPIg5) (Figure 1) and investigated their mode of action. This new class of branched-polyamines differs from dendrimers previously reported to possess anti-prion activity as they possess neutral rather than cationic surface groups due to the presence of maltose in their outer shell . They exhibit a markedly reduced toxicity over the more established cationic dendrimers yet still retain their anti-prion activity .
A) mPPIg5 is obtained by reductive amination of PPIg5 , . B) Molecular structure of cationic 4th generation poly(propylene imine) (PPIg4) with the smallest size used in biological experiments. C) Molecular weights for the dendrimers utilised in this study.
The efficacy of an anti-prion drug in a cell culture system is generally assessed by monitoring the elimination of protease resistant PrPSc over time through the use of PK digestion (to remove PrPC) and immunoblotting (to detect the remaining protease resistant PrPSc). As western blotting is quite cumbersome to perform and, at best, a semi-quantitative technique, we saw the potential to develop the highly quantitative and high throughput scrapie cell assay as a method of measuring the efficacy of anti-prion drugs. The standard scrapie cell assay (sSCA) is an ELISA spot assay and an alternative to the animal bioassay for the detection of prions . In the sSCA, susceptible cells are exposed for 4 days to a sample which potentially harbours infectious prions. If prions are within this sample they will infect the cells and propagate over time to detectable levels. The cells are then attached to a Multiscreen 96 well plate and undergo numerous treatments including a protease digestion step in which PrPC is removed and an immuno-detection step where protease resistant PrPSc is detected . Infected cells are visualised as spots on the Multiscreen plate membrane using a microscope and camera system for quantification. We used the ELISA spot portion of this system in reverse to monitor the decrease in PrPSc producing cells over time following the application of mPPIg5. To achieve this, the protease digestion step of the sSCA was altered to produce an assay more suitable for detecting the decrease in prion infected cells following treatment with a therapeutic agent. The modified assay, called the modified SCA (mSCA), detects all forms of protease resistant PrPSc (Table 1).
To determine how mPPIg5 was eliminating PrPSc from cells, we exploited the unique intracellular processing of the PrPSc protein. In prion infected cells, PrPC encounters PrPSc at an unidentified region sometime after reaching the plasma membrane and is converted to the misfolded isoform. About 1 hour after this event residues 23–88 at the N-terminus of PrPSc are removed by a proteolytic process that is believed to occur in an acidic endosome or lysosome –. The truncated PrPSc formed by this event is known as PrP27–30. PrP27–30 accumulates in lysosomes and has a half-life of ≥24 hours , . For the sake of clarity, in this study non-truncated protease resistant PrPSc will be referred to as Full Length PrPSc (FL PrPSc) and truncated protease resistant PrPSc will be referred to as PrP27–30.
In summary: PrPC →FL PrPSc→PrP27–30.
As FL PrPSc is short lived, its intracellular level is closely related to its production rate. If the synthesis of FL PrPSc is interfered with, the level of detectable FL PrPSc drops rapidly. Thus the level of FL PrPSc can be seen as a marker of the conversion of PrPC to misfolded forms. There are two basic mechanisms by which a drug can eliminate prions from a cell: (A) by increasing the degradation of pre-existing PrPSc or (B) by inhibiting the production of prions by blocking the conversion of PrPC to FL PrPSc. If a drug inhibits the conversion of PrPC to FL PrPSc, a rapid drop in FL PrPSc should occur. Thus, by monitoring the level of FL PrPSc we hoped to gain an insight into the mechanism by which mPPIg5 cleared PrPSc from cells.
A variation of the SCA, called the N terminal specific scrapie cell assay (nSCA), was created to quantify FL PrPSc. This assay was based on an assay previously developed by our laboratory to detect PrPSc in its nascent state . The nSCA specifically detects FL PrPSc. It does not detect the truncated form (PrP27–30) which represents the majority of PrPSc in the cell . The nSCA uses the protease trypsin to enable the detection of FL-PrPSc. Trypsin digests all PrPC and cleaves protease resistant PrPSc at positions 23, 24, 37 and 48. Although these are N-terminal cleavage sites, the majority of the N terminal including the Ocatpeptide Repeat region (OR) is left intact . An antibody (SAF32) directed against an epitope in the OR of the N-terminal can be used to detect FL PrPSc . This epitope is not present on PrP27–30 as the N terminal region is cleaved in the formation of PrP27–30 , . Therefore, the use of an N terminal antibody to differentiate between FL PrPSc and PrP27–30, and trypsin to remove PrPC but leave the majority of the N terminal of FL PrPSc intact, enables the nSCA to directly identify FL PrPSc present in a cell (Table 1). The sSCA is not capable of this as the PK used in this assay cleaves the N terminus of FL PrPSc reducing it to PrP27–30 (comparable to the cleavage that occurs in lysosomes). Therefore in the sSCA, FL PrPSc and PrP27–30 cannot be differentiated.
The ability to detect and quantify protease resistant PrPSc and FL PrPSc provides a powerful approach in assessing the efficacy and method of action of current and future therapeutics in the treatment of prion diseases. In this study the mSCA and nSCA were used to investigate the efficacy and mode of action of the anti-prion therapeutic mPPIg5. The assays demonstrated that mPPIg5 is a highly effective anti-prion drug which acts, at least in part, through the inhibition of PrPC to PrPSc conversion in 22L infected N2a cells.
Materials and Methods
Reagents and therapeutic compounds
All reagents used in this study were analytical grade, and unless otherwise stated, obtained from Sigma. The poly(propylene imine) generation four (PPIg4; DAB-Am32) and generation five (PPIg5; DAB-Am64) dendrimers were obtained from SyMO-Chem (Eindhoven, Netherland). PPIg5 dendrimers modified with a dense maltose shell (mPPIg5; Mw 44,500 g/mol) were prepared by a reductive amination of PPIg5 in the presence of maltose as described previously , . Dendrimer stock compounds were prepared as 20 mg/ml solutions in sterile H2O. Suramin was prepared as a 200 mg/ml stock solution in 0.9% NaCl in dH2O. STI571 (Stratech Scientific) was prepared as a 10 mM stock solution in dimethyl sulfoxide. NH4Cl was prepared as a 1M stock solution in Dulbecco's Modified Eagle Medium (DMEM)(Gibco). All stock solutions were sterilized by filtration through a 0.22 µm syringe filter (Millipore).
Cell culture and treatment
N2a cells were kindly donated by Dr. Byron Caughey (Rocky Mountain Laboratories, National Institutes of Health, Hamilton, MT, USA) . These were subcloned and infected with the murine adapted scrapie prion strain RML by the method of Bosque and Prusiner . N2a#58 cells and N2a#58 cells infected with the mouse adapted prion strain 22L (22LN2a#58), were kindly donated by Dr Sylvain Lehmann (Institut de Génétique Humaine du CNRS, Montpellier, France). N2a#58 cells are N2a cells transfected with mouse PrPa/a and produce ∼6x the normal levels of PrPC . All cell lines were maintained as monolayers at 37°C in 8% CO2 in cultivation media consisting of Dulbecco's Modified Eagle Medium (DMEM)(Gibco) supplemented with 2 mM glutamine, 100U/ml penicillin, 100 μg/ml streptomycin and 10% heat inactivated foetal bovine serum (FBS)(Gibco). In addition, the transfected N2a#58 cells were treated with 300 g/ml G418. The medium for all cell lines was replaced every 2–3 days and cells typically reached confluence after 4–5 days at which stage they were split for subculture. N2a and ScN2a used for metabolic labelling were cultured as described earlier . For treatment of cells with various therapeutics, cells were generally sub-passaged 24 hours prior to treatment at a dilution that allowed cells to be confluent at the end of treatment. Suramin, STI571, mPPIg5 and NH4Cl were diluted from stock solutions in regular culture media to the stated concentrations.
Scrapie Cell Assay
The ELISA portion of the Scrapie cell assay (SCA) was adapted from the protocol previously published by Klohn et al  and all steps were carried out at room temperature unless otherwise stated. The ELISPOT plate (MultiscreenHTS 96 well filtration plates with Immobilon-P transfer membrane, 0.45 µm; Millipore) was activated with 60 µl 70% methanol per well. The Methanol was removed by vacuum (MultiScreen vacuum; Millipore), wells washed twice with 160 µl PBS and 60 µl PBS added to each well to prevent drying out. Cells to be examined were washed twice with PBS and suspended in DMEM by gentle pipetting. Cells were diluted to 100,000 or 25,000 cells per ml depending on experiment and 200 µl of this dilution added to each well to give 20,000 or 5,000 cells per well. Cells were attached to the membrane by vacuum and the elispot plate placed in an incubator at 60°C for 1 hour without its lid. After 1 hour, the plate was either wrapped in cling film and stored at 4°C for up to two weeks or directly treated with protease.
Protease treatment varied depending on the experiment. For the standard scrapie cell assay 60 µl of PK (0.3 µg/ml for 5000 cells; 0.5 µg/ml for 20,000) diluted in lysis buffer (50 mM Tris HCl pH 8.0, 150 mM NaCl, 0.5% sodium deoxycholate, 0.5% Triton X-100) was used. For the modified and N terminal specific scrapie cell assay, 60 µl of trypsin (10 µg/ml for 5000 cells; 15 µg/ml for 20,000 cells) diluted in PBS (pH7.4) was utilised. Protease treatment was carried out at 37°C and 80rpm for one hour, followed by one wash with 160 µl PBS. The reaction was stopped by addition of 150 µl 2 mM PMSF (in PBS, pH 7.4) for 10 minutes. Cells were washed twice with 160 µl PBS, pH 7.4. and denatured by treatment with 120 µl 3M guanidinium thiocyanate (GSCN), 10mM Tris-HCl (pH 8) for 10 minutes. Following this wells were washed four times with PBS, pH 7.4 and incubated with 160 µl of Superblock (Pierce) for 1 hour. The superblock was removed and 60 µl primary antibody in TBS-T/1% non-fat milk powder (Marvel) added at the appropriate dilution for 1 hour – For the sSCA and mSCA, SAF83 was used at a final concentration of 20ng/ml. For the nSCA, SAF32 was employed at a final concentration of 266ng/ml. The wells were washed seven times with 160 µl TBS-T and incubated with 60µl ALP-conjugated anti-mouse secondary antibody (0.1 µg/ml in TBS-T/1% non-fat milk powder) for 1 hour. The wells were washed eight times with TBS-T and signal developed by incubation with 60 µl/well BCIP for 16 minutes in the dark. The development was stopped by two washes with 160 µl dH2O. The plastic casing at the back of the elispot plate was then removed and the wells washed a further two times with 160 µl dH2O. PrPSc positive cells were detected and quantified using the Zeiss Elispot software system and Zeiss AX-10 imager (Zeiss).
For analysis of intracellular protein content, confluent cells were washed twice with PBS, pH 7.4 and lysed with ice cold lysis buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 10 mM EDTA, 0.5% deoxycholic acid, 0.5% Triton X-100) for 5 minutes. Cells were detached from plate by pipetting and centrifuged at 1,000×g for 5 minutes to remove cellular debris. Protein concentration of the lysate was measured by BCA assay (Pierce) according to the manufacturer's instructions. For lysis of cells in 4% sarkosyl in PBS (pH 7.4), the same procedure as above was initially followed but lysis was performed with 4% sarkosyl in PBS (pH 7.4), not cellular lysis buffer. The lysate was subsequently homogenised by successive passage through 20, and 23 gauge needles. Protein concentration of the lysate was measured by BCA and the cell lysates were stored at −20°C and thawed on ice before use. For dendrimer treatment of lysates (lysate in 4% sarkosyl only) a final concentration of 2.4 mg/ml mPPIg5 was incubated with samples for 3 hours at 37°C and 450rpm. Protease resistant PrPSc content of all lysates was analysed by proteinase K (PK) treatment for 30 minutes at 37°C at a ratio of 250:1 using an amount of 100 µg cellular lysate (total protein) per sample. Reactions were stopped by addition of 5 mM PMSF. The sample was centrifuged at 16,000 g for 30 minutes, supernatant discarded and pellet re-suspended in 1× SDS sample buffer for immunoblot analysis.
Protein samples in 1× SDS sample buffer were incubated for 5 minutes at 95°C prior to electrophoresis on a 12.5% SDS polyacrylamide gel. After transfer (100 mV, 1 h) to a PVDF membrane (Millipore) and rinsing in TBST (TBS-0.5% Tween 20), unspecific binding sites were blocked by incubation in 5% dried milk powder (Marvel) in TBST for 1 h, with shaking (250 rpm). The membrane was washed five times in TBST (5 minutes each, shaking at 250 rpm), and incubated with SAF83 (SPI Bio, diluted to 20 ng/mL in TBST) overnight. The membrane was washed 5 times and exposed to goat anti-mouse IgG-ALP secondary antibody (Promega, diluted to 0.1 µg/ml in TBST) for 1.5 hours, followed by five additional washing steps in TBST (5 minutes each, shaking at 250 rpm). Blots were developed by exposure to 10 mls 5-Bromo-4-chloro-3-indolyl phosphate (BCIP) for 5 minutes, followed by two washes with dH2O. Developed membranes were digitized (imaged) using the Fujifilm LAS 4000.
Purification of PrP27–30 from prion infected N2a cells (ScN2a)
ScN2a cells were grown to confluence on 100 mm plates and washed twice with 4mls PBS (pH 7.4). Cells were lysed with ice cold 600 µl low detergent lysis buffer (10mM Tris, pH 7.4, 100 mM NaCl, 0.05% deoxycholic acid, 0.05% Triton X-100) and centrifuged at 1,000 g for 5 mins to remove cellular debris. Protein concentration of this postnuclear supernatant was measured by BCA (Pierce). The lysate was treated with proteinase K (PK) at a ratio of 1:50, protease to protein, for 2 hours at 37°C. The reaction was stopped by the addition of 5 mM PMSF (1/20 dilution of 100 mM PMSF). 500 µg aliquots of the lysate were transferred into 1.5 ml eppendorfs and centrifuged at 16,000g for 30 minutes. The supernatant was discarded and the pellet washed twice in 100 ml PBS (pH 7.4) by centrifugation at 16,000 g for 4 minutes. The resulting pellet was re-suspended in 50 µl PBS (pH 7.4) to give a final concentration of 10 µg/µl (before PK).
Inoculation of N2a cells with PrP27–30
N2a cells were seeded in a 96 well dish (for infection study) or 24 well dish (for nSCA validation) at a ratio of 20,000 and 150,000 cells per well respectively. Cells were incubated overnight in regular culture media at 37°C, 8% CO2. PrP27–30 purified from ScN2a cells was diluted to various degrees in cultivation media and added to the appropriate well. Cells were grown for 96 hours at 37°C and 8% CO2. The inoculated cells were either examined after 1 hour (nSCA validation) or cultured for four days before passaging at a 1/4 dilution, then cells cultured to confluence and passaged a further 3 times at 1/10 dilution before analysis by mSCA (Infection study).
Coverslips (13mm; Agar Scientific) were sterilised in 70% IMS and incubated overnight in Poly-D-Lysine (50 µg/ml). Following a rinse in sterile dH2O, coverslips were placed at the bottom of 6 well TC plates. N2a and N2a#58 cells were added at a dilution of 30,000 cells/well in cultivation media and let adhere to coverslips for 24 hours. After 24 hours, media was removed and cultivation media with either suramin (200 µg/ml) or mPPIg5 (20 µg/ml) added. Mock treated cells were treated with cultivation media +10 µl sterile dH2O. After 48 hours cells were fixed in 3% Paraformaldehyde for 20 minutes, quenched with 30 mM Glycine in PBS (pH 7.5) for 5 minutes and washed three times with PBS (pH 7.4) in 6 well TC plates. Cells to be permeabilized were treated with 0.1% Triton X-100 in PBS (pH 7.4) for 5 minutes and washed three times with PBS (pH 7.4). Primary antibody was applied for one hour (50 µl SAF32, 500 ng/ml in PBS). Coverslips were washed three times with PBS and 50 µl Alexa-488 conjugated anti-mouse secondary antibody (5 µg/ml in PBS; Invitrogen) applied. Following this, coverslips were washed once with PBS, treated for 3mins with the nuclear stain Hoechst 33342 (1:5000 in PBS; Invitrogen), and washed twice with PBS. Coverslips were mounted on glass slides using Mowiol and stored in the dark for 24 hours. Immunostained cells on coverslips were analysed by confocal microscopy using the Olympus FV1000 confocal microscope (Olympus). A 60x 1.35NA UPL SAPO objective was used. All images were acquired equally; 2x zoom, a scanning speed of 10.0 µs/pixel, with 3x kalman line averaging and sequential acquisition.
PIPLC analysis of cells
N2a#58 cells were seeded onto 60 mm plates and cultured for 24 hours. After 24 hours the media was removed, cells washed once in PBS (pH 7.4) and treatment media added for 48 hours. Treatment consisted of cultivation media with suramin (200 µg/ml), mPPIg5 (20 µg/ml) or sterile dH2O (10 µl) for mock treatment. After 48 hours media was removed and cells were mock treated with serum free DMEM at 37°C or treated for 2 hours with 0.5U/ml PIPLC in serum free DMEM. The media from all plates was collected and cells washed three times with PBS (pH 7.4) before being lysed as described previously. The protein in the media was ethanol precipitated and the PrPC content of this and the lysed cells (25 µg) determined by immunoblotting.
Metabolic labelling was carried out as described previously . Briefly, N2a cells cultivated in 3.5 cm dishes were transfected with 1 µg DNA by a liposome-mediated method using LipofectAMINE Plus reagent (Invitrogen) according to the manufacturer's instruction. The mouse PrP construct used contain a 3F4 tag . Cells were starved for 30 minutes in methionine-free modified Eaglés medium (Invitrogen) and subsequently labelled for 1 hour with 300 µCi/ml L-[35S] methionine (Hartmann Analytics; >37 TBq/mmol) in methionine-free modified Eaglés medium (Invitrogen). For the chase, the labelling medium was removed, and cells were washed twice and incubated in complete medium for 4 hours. When indicated, maltose modified Poly(propylene imine) generation 5 (mPPIg5) was present during the starving, labelling and chase periods (final concentration 20 µg/ml). PrP was analysed by immunoprecipitation with the monoclonal 3F4 antibody , . The immunopellet was analysed by SDS-PAGE and autoradiography .
Efficacy of mPPIg5
The modified scrapie cell assay (mSCA) was developed in this study and is used to quantify the decrease in PrPSc producing cells over time following treatment with a therapeutic. In comparison to the standard scrapie cell assay (sSCA) which uses PK in lysis buffer, the mSCA employs trypsin in PBS as the protease digestion step necessary to remove PrPC. This produces more intense and compact cells which are easier to quantify and results in an assay better able to detect a decrease in PrPSc producing cells over time (Figure S1). The mSCA was used to investigate the efficacy of maltose modified PPI dendrimers (mPPIg5) in curing prion infected cells. mPPIg5 has previously been shown to eliminate PrPSc from RML infected N2a cells (ScN2a) . To examine the ability of mPPIg5 to cure cells infected with strains other than RML, 22L infected N2a#58 cells (22LN2a#58) were treated with 20 µg/ml mPPIg5 for increasing periods of time and cells assessed via the modified scrapie cell assay (mSCA) (Figure 2A). The mSCA illustrates that mPPIg5 eliminates protease resistant PrPSc from 22LN2a#58 cells in a highly efficient manner and highlights the promise of modified dendrimers as anti-prion therapeutics. The traditional method of PrPSc detection – PK digestion and immunoblot – was used to confirm the result (Figure 2B). The optimum treatment concentration of mPPIg5 was also determined using the mSCA (Figure S2) and found to be in agreement with the literature at 10–20 µg/ml .
. A) 22LN2a#58 cells were either treated with 20 µg/ml mPPIg5 or mock-treated for increasing lengths of time before analysis of cells for PrPSc content via mSCA. The % difference in PrPSc content between mPPIg5 and mock treated cells at each time point was calculated and the decrease in PrPSc over time plotted. Error bars represent SD; n = 3. B) 22LN2a#58 cells were treated with 20 µg/ml mPPIg5 for increasing lengths of time before detection of protease resistant PrPSc via PK digestion and immunoblotting (lanes 3–10). Samples in lane 2 were not treated whilst samples in lane 1 were not treated or PK digested. Apparent molecular mass based on migration of protein standards is indicated for 17, 25, and 30 kDa. n = 3.
Intracellular method of action of mPPIg5
Dendrimers are believed to achieve their anti-prion effect by acting directly on PrPSc within lysosomes and rendering them sensitive to proteases . The ability of dendrimers to render PrPSc from brain homogenate protease sensitive in vitro supports this , . mPPIg5 eliminated protease resistant PrPSc from 22L infected N2a#58 cells (Figure 2), so it was expected that mPPIg5 would also be effective at eliminating protease resistant PrPSc from lysates derived from 22L infected N2a#58 cells. However, whilst mPPIg5 was able to eliminate protease resistant PrPSc from lysates derived from RML infected cells in vitro, it had no effect on lysates derived from 22L infected cells (Figure 3A). In contrast, intracellular treatment with mPPIg5 eliminated protease resistant PrPSc from both RML (Figure 3B) and 22L infected cells (Figure 2). This suggested that the method by which mPPIg5 eliminated PrPSc intracellularly and in vitro may be different – mPPIg5 dendrimers may not render PrPSc protease sensitive in vivo; the presumed mode of action for dendrimers. They may interfere with the PrPC → PrPSc conversion process. This possibility was investigated by developing a variation of the SCA capable of quantifying Full Length PrPSc (FL PrPSc) called the N terminal specific SCA (nSCA).
A) RML infected N2a cells and 22L infected N2a#58 cells were lysed in 4% sarkosyl (in PBS pH 7.4). 100 µg of lysate was then left untreated or treated with 2.4 mg/ml of mPPIg5 dendrimers for 3 hours before analysis for protease resistant PrPSc content by PK digestion and immunoblot. B) RML infected N2a cells were treated with increasing concentrations of mPPIg5 for 4 days before analysis by PK digest and immunoblot for PrPSc. Apparent molecular mass based on migration of protein standards is indicated for 17, 25, and 30 kDa in both panel A and B. n = 3.
The nSCA was created to directly quantify FL PrPSc. To validate this assay and confirm that it only detects FL PrPSc and not PrPC or PrP27–30, N2a cells were inoculated with exogenous PrP27–30 for 1 hour and assayed by the mSCA and nSCA (Figure 4A). (For details on production and validation of PrP27–30 see Fig S3). The nSCA did not detect PrP27–30. The mSCA (which can detect PrP27–30) acted as a positive control to show that PrP27–30 was associated with the cells and illustrated a dose response curve matching the dilutions of inoculates used (Figure 4A).
A) N2a cells and B) ScN2a cells were inoculated for 1.5 hours with increasing dilutions of PrP27–30. The infective media was removed and replaced with regular DMEM for an additional 3 hours before cells were repeatedly washed with PBS and 20,000 cells attached per well of an ELISPOT plate. Cells were examined via the nSCA and mSCA. Positive result is defined as >30 spots/20,000 cells. The software used to count spots (infected cells) cannot count accurately above 1000 spots so a dose response curve is not observed with the mSCA for the ScN2a cells inoculated with PrP27–30. Error bars represent SD; n = 2.
To demonstrate that the nSCA can detect FL PrPSc, RML infected N2a cells (ScN2a) were inoculated with PrP27-30 and nSCA and mSCA performed (Figure 4B). The nSCA detected the endogenous FL PrPSc within the ScN2a cells but not the additional exogenous PrP27–30. The mSCA detected both the endogenous FL PrPSc and the exogenous and endogenous PrP27–30. These results demonstrate the nSCA's ability to differentiate between FL PrPSc and PrP27–30 in prion infected cells. Having demonstrated that the nSCA can selectively detect FL PrPSc, we sought to determine if the nSCA could be used to deduce mPPIg5′s intracellular mode of action.
The hypothesis was:
- If mPPIg5 interfered with the conversion of PrPC to FL PrPSc, a rapid decrease in FL PrPSc levels would be expected; PrPC to FL PrPSc conversion would be inhibited and so no new FL PrPSc would be produced. Existing FL PrPSc is naturally cleaved to PrP27–30 within ∼1 hour of its synthesis ,  and so FL PrPSc levels would be expected to drop rapidly.
- If mPPIg5 acted in the lysosome to increase the degradation of PrPSc, no short term effect would be observed on FL PrPSc; mPPIg5 may induce some degradation of FL PrPSc, but PrPC conversion to FL PrPSc would not be significantly perturbed and so FL PrPSc levels would not be expected to drop rapidly over the short term.
To validate this approach, two drugs with an established anti-prion mode of action were also examined. Suramin is a drug which achieves its anti-prion effect by inhibiting the conversion of PrPC to PrPSc. It achieves this by inhibiting the regular trafficking of PrPC and causing its aggregation as non-protease resistant aggregates in a post ER/Golgi compartment. This alteration in trafficking prevents its conversion to PrPSc . STI571 is a tyrosine kinase inhibitor whose effect on c-abl tyrosine kinase results in the increased lysosomal degradation of PrPSc . We hypothesised that suramin would have a dramatic effect on FL PrPSc levels over the first 48 hours of treatment whilst STI571 would have a minimal effect over this time period. The mode of action of mPPIg5 could then be deduced by correlating its effect on FL PrPSc with these drugs.
To investigate this, 22LN2a#58 cells were treated with suramin (200 µg/ml), STI571 (10 µM) and mPPIg5 (20 µg/ml) for increasing periods of time before analysis for FL PrPSc levels via the nSCA and immunoblotting (Figure 5). Both suramin and mPPIg5 treatment resulted in a rapid decrease of FL PrPSc levels with ∼80% of FL PrPSc eliminated after 12 hours. Contrary to expectations, STI571 treatment also led to a rapid decrease in FL PrPSc levels, though the decline in FL PrPSc levels was less pronounced with ∼50% eliminated after 12 hours. The rapid loss in FL PrPSc levels upon STI571 treatment was unexpected. Pulse chase experiments have demonstrated that STI571 does not interfere with the production of protease resistant PrPSc . Production of protease resistant PrPSc must involve the production of FL PrPSc (PrPC → FL PrPSc → PrP27–30). Therefore the decrease in FL PrPSc upon STI571 treatment while protease resistant PrPSc production continued unabated was puzzling. One explanation is that STI571 may increase the rate of truncation of FL PrPSc. This would lead to a rapid decrease in detectable FL PrPSc without affecting the production of protease resistant PrPSc. STI571 inhibits the tyrosine kinase c-Abl, which is thought to result in the increased lysosomal degradation of PrPSc . Given its effect on the lysosome, the ability of STI571 to increase the N terminal truncation of FL PrPSc is therefore plausible. Although not alluded to by the authors, this scenario is also supported by examination of the original results from Ertmer et al (Figure 4A, lane 1 vs 3; Ertmer et al., 2004).
. A) 22LN2a#58 cells were treated with either STI571 (10 µm), suramin (200 µg/ml), mPPIg5 (20 µg/ml) or mock treated for increasing periods of time before analysis for FL PrPSc content by nSCA. The % difference in PrPSc content between therapeutically treated and mock treated cells at each time point was calculated for each drug (STI571, Suramin and mPPIg5) and the decrease in FL PrPSc over time plotted. Error bars represent SD; n = 3. B) To validate the result, 22LN2a#58 cells treated with STI571 (10 µm), suramin (200 µg/ml) and mPPIg5 (20 µg/ml) for various periods of time were also lysed and analysed for FL PrPSc content by trypsin digestion and immunoblotting with SAF32 (Lanes 3–10). Samples in lane 2 were not treated whilst samples in lane 1 were not treated or PK digested. Apparent molecular mass based on migration of protein standards is indicated for 17, 25, and 30 kDa. n = 3.
The rapid loss of FL PrPSc observed in mPPIg5 treated cells could be explained by an increased rate of FL PrPSc N terminal truncation. NH4Cl was used to examine this possibility. NH4Cl inhibits N terminal truncation of FL PrPSc by raising the pH of the acidic endosome where this cleavage occurs. NH4Cl does not interfere with the production of de novo PrPSc or the biogenesis and trafficking of PrPC .
It was hypothesised:
- If a compound inhibits the conversion of PrPC to FL PrPSc, no difference between cells treated in the presence and absence of NH4Cl should be observed; FL PrPSc is not being produced so NH4Cl induced inhibition of truncation should have no effect.
- If an anti-prion compound solely achieves its effect by increasing the degradation of PrPSc isoforms (including FL PrPSc), prion infected cells treated in the presence of NH4Cl should produce a higher level of FL PrPSc than cells treated in the absence of NH4Cl. There are at least two ways NH4Cl can achieve this. a) NH4Cl may inhibit the anti-prion action of a drug by raising the pH of the lysosome. In this instance, PrPSc isoforms (including FL PrPSc) would not be degraded and so an increase in the level of FL PrPSc would be observed in cells treated in the presence of NH4Cl over cells treated in the absence of NH4Cl. b) In the presence of NH4Cl, an anti-prion drug may still degrade PrPSc isoforms. However NH4Cl treated cells will possess an increased level of FL PrPSc. Cells treated with an anti-prion drug in the presence of NH4Cl will therefore display a higher level of FL PrPSc than cells treated in the absence of NH4Cl as there is more FL PrPSc to degrade.
To examine this hypothesis, 22LN2a#58 cells were treated for 48 hours with mPPIg5 (20 µg/ml), suramin (200 µg/ml) or STI571 (10 µM) in the presence or absence of 2 mM NH4Cl and analysed by nSCA (Figure 6). In the presence of NH4Cl, 22LN2a#58 control cells registered an increase in FL PrPSc over non NH4Cl treated control cells (Figure 6). This confirms that NH4Cl produces an increase in FL PrPSc by preventing its truncation to PrP27–30.
22LN2a#58 cells were mock treated or treated with mPPIg5 (20 µg/ml), STI571 (10 µM) or suramin (200 µg/ml) in the presence or the absence of 2 mM NH4Cl for 48 hours before analysis for FL PrPSc content via nSCA. The number of FL PrPSc containing cells in 20,000 mock treated control cells (- NH4Cl) is taken as the 100% value on the Y axis. All subsequent results are calculated from this. Results marked a, b, c and d are all statically significantly different from one another (p<0.001); Analysed using a Two-way ANOVA for PrPres, Dendrimer × NH4Cl (F4,88 = 7.99; P<0.001). Post-hoc analysis by Tukeys test; Error bars represent SD; n = 3.
Both mPPIg5 and suramin treatment of 22LN2a#58 cells produced a decrease in FL PrPSc that was unaffected by NH4Cl (Figure 6). This indicates that mPPIg5 is capable of inhibiting the conversion of PrPC to FL PrPSc. Suramin served as a control in this experiment for a drug known to inhibit the conversion of PrPC to PrPSc .
STI571 was used as a control for a drug known to increase the degradation of pre-existing PrPSc . STI571 treatment of 22LN2a#58 cells resulted in a decrease of FL PrPSc that was partially reversed by NH4Cl (Figure 6). NH4Cl inhibition of STI571′s ability to clear PrPSc was previously reported and attributed to NH4Cl raising the pH of the acidic lysosome where STI571 induced degradation of PrPSc was thought to occur .
From this experiment we can conclude that mPPIg5 inhibits the conversion of PrPC to FL PrPSc. It should be noted that these results make no assumption about mPPIg5′s ability to increase the degradation of PrPSc, though it does rule this out as being mPPIg'5s sole mechanism of action.
A possible explanation for mPPIg5′s ability to inhibit the conversion of PrPC to PrPSc is that mPPIg5 interferes with the biogenesis or subcellular localization of the PrPC protein. mPPIg5 may prevent PrPC from localizing in lipid rafts at the plasma membrane and thus prevent its conversion to PrPSc in a similar manner to which suramin works for example . To examine this possibility, N2a#58 cells grown on coverslips were treated with mPPIg5 or suramin and PrPC localization examined via confocal microscopy (Figure 7A). Non-permeabilized cells were used to specifically examine PrPC levels at the plasma membrane whilst permeabilized cells were used to detect all PrPC within the cell. The results illustrate that mPPIg5 treatment has no effect on the localization of PrPC, which is still predominantly found at the plasma membrane. In agreement with previous results, suramin treatment of cells inhibited PrPC localization at the plasma membrane and instead caused PrPC aggregation in what appears to be a post-ER/Golgi compartment .
A) Confocal microscopy was used to examine the cellular localization of PrPC. N2a#58 cells grown on coverslips were mock treated, treated with 20 µg/ml mPPIg5 or treated with 200 µg/ml suramin for 48 hours. Cells were then permeabilized or left intact before immuno-staining with SAF32 and Alexa488 secondary antibody for PrPC. Hoechst 33342 was used to stain DNA. All images were acquired using equal settings. n = 2. B) Phosphatidylinositol-specific phospholipase C (PIPLC) was used to validate the confocal microscopy result. N2a#58 cells were treated with 20 µg/ml mPPIg5 (lanes 2, 4, 6 and 8) or mock treated (lanes 1, 3, 5 and 7) for 48 hours. Cells were washed with PBS then treated for two hours with 0.5U/ml PIPLC in serum free DMEM (lanes 3, 4, 7 and 8) or mock treated with serum free DMEM (lanes 1, 2, 5 and 6). The media was collected, ethanol precipitated and examined for PrPC by immunoblotting with SAF83 antibody (lanes 5–8). The remaining cells were lysed and a portion examined for PrPC by immunoblot (lanes 1–4). Apparent molecular mass based on migration of protein standards is indicated for 17, 25, and 30 kDa. C) Biosynthesis of PrPC was examined by metabolic labelling. N2a cells were transfected with PrPC and labelled with [35S] methionine for 1 hour. After labelling cells were either analysed directly (Pulse), or incubated in fresh medium for additional 4 h (Chase). When indicated, mPPIg5 was present during the starving, labelling and chase periods (final concentration 20 µg/ml). PrP was immunoprecipitated by using the monoclonal anti-PrP antibody 3F4 and analysed by SDS-PAGE and autoradiography. Apparent molecular mass based on migration of protein standards is indicated for 16, 22, and 36 kDa.
To confirm the confocal microscopy result, phosphatidylinositol-specific phospholipase C (PIPLC) was utilised. mPPIg5 and mock treated N2a#58 cells were incubated with PIPLC, and following this the cell media was collected and treated cells lysed. The media was ethanol precipitated to obtain all protein. Both this and the cellular lysate were then examined for PrPC content by immunoblot (Figure 7B). The cellular lysate for both the control and mPPIg5 treated cells exhibited a significant drop in PrPC content following PIPLC treatment indicating PrPC was removed from the plasma membrane. This PrPC was detectable in the media, though at a lower level than expected. This discrepancy can be explained by a diminished immunoblot signal from PrPC cleaved by PIPLC . There was no detectable difference between the amount of PrPC released from the plasma membrane in the control and mPPIg5 treated cells indicating that mPPIg5 had no effect on PrPC localization.
To ensure PrPC synthesis was not affected by mPPIg5 treatment, N2a cells were pulse radio labelled with [35S] methionine in the presence or absence of mPPIg5 and the synthesis of PrPC monitored (Figure 7C). mPPIg5 treated cells produced an equal amount of PrPC as the control cells indicating mPPIg5 has no effect on PrPC synthesis.
Maltose modified PPI (mPPI) dendrimers are a relatively new class of anti-prion compounds with immense potential due to their low cytotoxicity  and ability to cross the blood-to-brain barrier . In this study we developed and utilised novel forms of the scrapie cell assay to demonstrate that the maltose modified PPI dendrimer, mPPIg5, is a potent anti-prion drug which inhibits the conversion of PrPC to PrPSc. In addition, we demonstrate that mPPIg5 does not interfere with the biogenesis or processing of the regular PrP isoform, indicating that modified dendrimers possess significant potential as anti-prion therapeutics and as agents for investigating the nature of prion diseases.
To deduce mPPIg5′s intracellular mode of action, a novel assay called the N terminal specific SCA (nSCA) was developed. The nSCA was used to demonstrate that mPPIg5 inhibits the conversion of PrPC to PrPSc (Figure 6). This is novel as previous studies have suggested that dendrimers which eliminate PrPSc from cells achieve their effect by enhancing the degradation of PrPSc in acidic endosomes/lysosomes , . This working hypothesis was based on three observations:
- The alkalising lysomotrophic agent chloroquine, inhibited the elimination of prions by dendrimers (PEI) .
- Confocal microscopy showed dendrimers (PPI) localizing in lysosomes .
- The in vitro elimination of protease resistant PrPSc by dendrimers (PEI and PPI) was greatest at an acidic pH , .
Collectively, these findings argue that dendrimers with anti-prion activity achieve their effect by increasing the degradation of PrPSc. However when examined individually, each of the arguments quickly becomes less robust. For example, chloroquine has multiple effects on cells in addition to raising its lysosomal pH such as altering protein trafficking and endocytosis , . In addition, NH4Cl, another alkalising lysomotrophic agent, does not inhibit the effect of PEI dendrimers  suggesting alkalisation of acidic compartments alone is not sufficient. The finding that the in vitro elimination of protease resistant PrPSc by dendrimers was greatest at an acidic pH is also not conclusive as the in vitro anti-prion action of dendrimers appears to involve the denaturation of PrPSc and so an acidic pH enhancing this is not surprising. In addition, an acidic pH is not necessary for the in vitro anti-prion effect of dendrimers, it just optimizes it, and so an acidic environment intracellularly cannot be automatically assumed (unpublished data). Finally, the fact that PPI dendrimers localize predominantly in lysosomes is not surprising as most endocytosed materials will end up there. Hence the argument for various dendrimers eliminating prions by increasing their lysosomal degradation is less robust than first impressions would lead one to believe. That said, the ability of numerous dendrimers to render PrPSc protease sensitive in vitro does suggest that dendrimer induced intracellular degradation of PrPSc is quite possible. The approach employed in this study makes no presumptions on whether or not mPPIg5 interferes with the degradation of PrPSc. It solely examines the issue of whether or not the conversion of PrPC to PrPSc is being inhibited. For drugs such as STI571 which do not inhibit the conversion process but clearly eliminate prions from infected cells, the nSCA can be used to determine that they must work by increasing degradation through a process of elimination. However the nSCA system cannot be used to tell whether a drug works by both inhibiting conversion and increasing degradation of PrPSc or by solely inhibiting the conversion of PrPC to PrPSc. Hence it is quite possible that mPPIg5 is able to eliminate prions from a cell by both inhibiting the conversion of PrPC to misfolded forms and increasing the degradation of PrPSc as in vitro experiments suggest.
Evidence for other dendrimers inhibiting the conversion of PrPC to PrPSc is indirectly supplied from previous studies. An investigation with permanently charged quaternized dendrimers showed that versions of these dendrimers which demonstrated no activity against prions in vitro, are capable of eliminating prions intracellularly and inhibiting PrP aggregate formation in PMCA experiments. This suggested to the authors that something other than dendrimer induced degradation of prions may be taking place such as inhibition of PrPC to PrPSc conversion . In this study we demonstrated a similar result whereby mPPIg5 was not effective against 22L in an in vitro setting but highly effective in an intracellular setting (Figure 3). Additionally, experiments with the PAMAM generation 7 (PAMAMg7) dendrimer have demonstrated that this polyamine causes a dramatic accumulation of an insoluble, protease-sensitive PrP aggregate, believed to be produced directly from PrPC. It is possible that this aggregate inhibits the formation of PrPSc by sequestering PrPC . Our study did not reveal any evidence of such non-infectious PrP aggregates following treatment with mPPIg5 suggesting this may be an effect specific to PAMAM or perhaps even high generation dendrimers.
mPPIg5 has no effect on PrPC synthesis and localization as demonstrated by confocal microscopy, pulse chase and PIPLC experiments. Since mPPIg5 has no discernible effect on PrPC, how then does it inhibit the conversion of PrPC → PrPSc? There are a number of possibilities. mPPIg5 may competitively inhibit the interaction between PrPC and PrPSc. Or it may interfere with components of PrPSc formation which have not yet been identified such as short-lived PrPC → PrPSc intermediates or potential co-factors like RNA which are necessary for PrPSc formation . Alternatively PrPSc trafficking may be interfered with to the extent that it is no longer available for the conversion of PrPC.
Perhaps the most likely explanation is that mPPIg5 alters the structure of PrPSc to such an extent that it is no longer capable of initiating the misfolding of PrPC. Evidence for dendrimers effecting the structure of PrPSc comes from in vitro studies with prion infected brain homogenate, demonstrating that various dendrimers appear to denature PrPSc molecules and render them susceptible to proteolysis , . Additionally, Fourier transform infrared spectroscopy and electron microscopy studies have demonstrated that purified prions treated with PPI dendrimers lose β-sheet structure and become disaggregated . Dendrimers altering the confirmation of the PrPSc molecule can thus serve as an explanation for both the in vitro and intracellular activity of all dendrimers. One could envisage dendrimers interacting with the PrPSc molecule (both in vitro and intracellularly) and altering its structure in a process that is governed by the original confirmation of the PrPSc molecule (influenced by the type of prion strain) and on the chemical nature of the dendrimer (dependant on a combination of the dendrimers size, structure, charge and density of reactive surface groups). In some instances, the interaction will alter the PrPSc structure to the extent that it becomes susceptible to proteolysis, both in an in vitro and intracellular setting. In other cases the interaction will not be sufficient to render PrPSc susceptible to proteolysis but it will alter the PrPSc molecule to the extent that it can no longer convert PrPC to the misfolded form. This would explain how some dendrimers apparently fail to reduce protease resistant PrPSc in vitro but can be effective intracellularly. Additionally, such a scenario would allow a dendrimer to eliminate prions intracellularly by both increasing their degradation as the original experiments in this area suggest , ,  and/or eliminate prions by inhibiting the conversion of PrPC to PrPSc as some of the more recent studies in this area, including our own, suggest , .
Dendrimers affecting the structure of misfolded PrP may also explain how numerous dendrimers (including mPPI) inhibit the fibrilization of PrP peptides in vitro , –. This ability is believed to be due to dendrimers increasing the fibril breakage rate or blocking the end of growing fibrils , . Both of these scenarios are possible in an intracellular setting. However dendrimers blocking the end of growing fibrils cannot explain the ability of various dendrimers to reduce PrPSc in prion infected brain homogenate , , , . Dendrimers increasing the fibril breakage rate on the other hand can explain this ability and again may be linked back to specific dendrimers having an effect on the structure of misfolded PrP. Hence an ability to alter the structure of PrPSc can explain the various anti-prion activities of dendrimers in an intracellular and in vitro setting. Whilst it is possible that different dendrimers may achieve their anti-prion effect through a variety of mechanisms, Occam′s razor dictates that a single explanation is the most likely. Additional experiments are necessary before this hypothesis could be accepted. What this study demonstrates is that mPPIg5 inhibits the conversion of PrPC to PrPSc. Understanding the basis of the anti-prion activity of other dendrimers remains an exciting challenge.
This study also involved the development of the modified SCA (mSCA) as a high throughput and fully quantitative system for monitoring the elimination of prions in infected cells over time. The traditional method for assessing a drug's anti-prion effect in an intracellular setting relies on the PK digestion and immunoblotting of samples followed by densitometry to quantify the result. Such immunoblot based assays are labour intensive and the densitometry involved generates, at best, a semi-quantitative result. The mSCA is a marked improvement over these traditional methods. It offers a number of advantages in speed and throughput for the assessment of the efficacy of anti-prion drugs and is suitable for the mass screening of compounds.
In conclusion, this study highlights how the mSCA and nSCA represent exciting new tools for investigating the efficacy and mode of action of novel anti-prion compounds. These assays were utilised to demonstrate that mPPIg5 is an effective anti-prion compound capable of inhibiting the conversion of PrPC to PrPSc. Understanding how a drug works is a vital component in maximising its performance. By establishing that mPPIg5 interferes with the conversion of PrPC to PrPSc, this study will help determine what other drugs may enhance this effect. The low cytotoxicity of mPPIg5 and the recently demonstrated ability of maltotriose dendrimers to cross the blood to brain barrier  suggests that mPPIg5 is one of the most promising anti-prion therapeutics currently available and worthy of further investigation.
ELISPOT after mSCA and sSCA. Elispot well after the mSCA and the sSCA of N2a and ScN2a cells. The spots visible on the ELISPOT membrane reflect cells containing PrPSc. The spots produced by the mSCA are sharper and more intense than those produced by sSCA. All images were captured in maximum focus and not subsequently altered in any way.
Optimum mPPIg5 treatment concentration. 22LN2a#58 cells were treated with increasing concentrations of mPPIg5 for A) 26 hours or B) 72 hours before analysis by mSCA (20,000 cells/well). The optimum concentration of mPPIg5 for PrPSc elimination was found to be 10–20 µg/ml, which is similar to that calculated for the elimination of PrPSc in RML infected cells 14). Error bars represent SD; n = 3.
Preparation and validation of PrP27–30. A) To generate PrP27–30 free of any traces of FL PrPSc an innovative method was employed. ScN2a cells were lysed in a minimum detergent lysis buffer to reduce the toxicity of the extract. Following this, PrPSc present in the lysate was reduced to PrP27–30 using an extended PK digest and wash protocol. To ensure that the PrP27–30 produced was N terminally cleaved an immunoblot was performed with monoclonal antibody SAF32 (specific for the N terminal of PrP; lane 1 and 2) and SAF83 (specific for the protease resistant core of PrP27–30; lane 3 and 4). Samples in lane 1 and 3 are non-protease treated controls whilst samples in lane 2 and 4 were PK treated for 2 hours. Apparent molecular mass based on migration of protein standards is indicated for 17, 25, and 30 kDa. B) The infectivity of the PrP27–30 produced (and hence its similarity to endogenous PrP27–30) was examined by the scrapie cell assay. A highly susceptible subclone of N2a cells (N2a29) and a subclone resistant to prion infection (N2a6) created in our laboratory were seeded onto a 96 well TC plate and inoculated with various dilutions of PrP27–30 purified from ScN2a cells. The cells were passaged four times to dilute the original inoculate and then examined via mSCA for infected N2a cells. A 1/10 dilution of PrP27–30 proved toxic to the cells. N2a cells resistant to prion infection (N2a6) were used to show that none of the original PrP27–30 inoculate was detectable after 4 passages. Error bars represent SD; n = 3 (technical, not biological repeats). The immunoblotting and infectivity study demonstrated that the PrP27–30 prepared from ScN2a cells lacked the N terminal but retained its protease resistant core and the ability to infect susceptible cells.
Conceived and designed the experiments: JM JT MR. Performed the experiments: JM MF UR SW JS DA. Analyzed the data: JM MF UR SW JS JT DA MR. Contributed reagents/materials/analysis tools: JT JS DA MR. Wrote the paper: JM UR JS JT DA MR.
- 1. Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216: 136–144.
- 2. Prusiner SB (1998) Prions. Proc Natl Acad Sci U S A 95: 13363–13383.
- 3. Caughey B, Race RE (1992) Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem 59: 768–771.
- 4. Caughey B, Raymond GJ (1993) Sulfated polyanion inhibition of scrapie-associated PrP accumulation in cultured cells. J Virol 67: 643–650.
- 5. Priola SA, Raines A, Caughey WS (2000) Porphyrin and phthalocyanine antiscrapie compounds. Science 287: 1503–1506.
- 6. Supattapone S, Nguyen HO, Cohen FE, Prusiner SB, Scott MR (1999) Elimination of prions by branched polyamines and implications for therapeutics. Proc Natl Acad Sci U S A 96: 14529–14534.
- 7. Supattapone S, Wille H, Uyechi L, Safar J, Tremblay P, et al. (2001) Branched polyamines cure prion-infected neuroblastoma cells. J Virol 75: 3453–3461.
- 8. Gilch S, Winklhofer K, Groschup M, Nunziante M, Lucassen R, et al. (2001) Intracellular re-routing of prion protein prevents propagation of PrPSc and delays onset of prion disease. EMBO J 20: 3957–3966.
- 9. Ertmer A, Gilch S, Yun S, Flechsig E, Klebl B, et al. (2004) The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem 279: 41918–41927.
- 10. Doh-Ura K, Iwaki T, Caughey B (2000) Lysosomotropic agents and cysteine protease inhibitors inhibit scrapie-associated prion protein accumulation. J Virol 74: 4894–4897.
- 11. Ghaemmaghami S, Ullman J, Ahn M, St Martin S, Prusiner S (2009) Chemical induction of misfolded prion protein conformers in cell culture. J Biol Chem 285: 10415–10423.
- 12. Lim Y, Mays C, Kim Y, Titlow W, Ryou C (2010) The inhibition of prions through blocking prion conversion by permanently charged branched polyamines of low cytotoxicity. Biomaterials 31: 2025–2033.
- 13. Klajnert B, Appelhans D, Komber H, Morgner N, Schwarz S, et al. (2008) The influence of densely organized maltose shells on the biological properties of poly (propylene imine) dendrimers: new effects dependent on hydrogen bonding. Chem Eur J 14: 7030–7041.
- 14. Fischer M, Appelhans D, Schwarz S, Klajnert B, Bryszewska M, et al. (2010) Influence of Surface Functionality of Poly (propylene imine) Dendrimers on Protease Resistance and Propagation of the Scrapie Prion Protein. Biomacromolecules 11: 1314–1325.
- 15. Klohn PC, Stoltze L, Flechsig E, Enari M, Weissmann C (2003) A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. Proc Natl Acad Sci U S A 100: 11666–11671.
- 16. Caughey B, Raymond GJ, Ernst D, Race RE (1991) N-terminal truncation of the scrapie-associated form of PrP by lysosomal protease (s): implications regarding the site of conversion of PrP to the protease-resistant state. J Virol 65: 6597–6603.
- 17. Borchelt DR, Taraboulos A, Prusiner SB (1992) Evidence for synthesis of scrapie prion proteins in the endocytic pathway. J Biol Chem 267: 16188–16199.
- 18. Taraboulos A, Raeber AJ, Borchelt DR, Serban D, Prusiner SB (1992) Synthesis and trafficking of prion proteins in cultured cells. Mol Biol Cell 3: 851–863.
- 19. Waldron S (2008) Assessing Acute Infection in Prion Disease using Native PrPSc Detection methods [Ph.D. thesis]. Dublin: University College Dublin. 1–155 p.
- 20. McKinley MP, Taraboulos A, Kenaga L, Serban D, Stieber A, et al. (1991) Ultrastructural localization of scrapie prion proteins in cytoplasmic vesicles of infected cultured cells. Lab Invest 65: 622–630.
- 21. Yam AY, Gao CM, Wang X, Wu P, Peretz D (2010) The Octarepeat Region of the Prion Protein Is Conformationally Altered in PrPSc. PLoS One 5: e9316.
- 22. Klebe R, Ruddle F (1969) Neuroblastoma: cell culture analysis of a differentiating stem cell system. J Cell Biol 43: 69.
- 23. Bosque PJ, Prusiner SB (2000) Cultured Cell Sublines Highly Susceptible to Prion Infection. J Virol 74: 4377–4386.
- 24. Nishida N, Harris DA, Vilette D, Laude H, Frobert Y, et al. (2000) Successful Transmission of Three Mouse-Adapted Scrapie Strains to Murine Neuroblastoma Cell Lines Overexpressing Wild-Type Mouse Prion Protein. J Virol 74: 320–325.
- 25. Winklhofer KF, Heske J, Heller U, Reintjes A, Muranyi W, et al. (2003) Determinants of the in vivo folding of the prion protein. A bipartite function of helix 1 in folding and aggregation. J Biol Chem 278: 14961–14970.
- 26. Miesbauer M, Pfeiffer NV, Rambold AS, Muller V, Kiachopoulos S, et al. (2009) alpha-Helical domains promote translocation of intrinsically disordered polypeptides into the endoplasmic reticulum. J Biol Chem 284: 24384–24393.
- 27. Kascsak RJ, Rubenstein R, Merz PA, Tonna-DeMasi M, Fersko R, et al. (1987) Mouse polyclonal and monoclonal antibody to scrapie-associated fibril proteins. J Virol 61: 3688–3693.
- 28. Winklhofer KF, Heller U, Reintjes A, Tatzelt J (2003) Inhibition of complex glycosylation increases the formation of PrPsc. Traffic 4: 313–322.
- 29. Nishina KA, Supattapone S (2007) Immunodetection of glycophosphatidylinositol-anchored proteins following treatment with phospholipase C. Anal Biochem. 363: 318–320.
- 30. Janaszewska A, Ziemba B, Ciepluch K, Appelhans D, Voit B, et al. (2012) The biodistribution of maltotriose modified poly (propylene imine)(PPI) dendrimers conjugated with fluorescein–proofs of crossing blood–brain–barrier. New Journal of Chemistry 36: 350–353.
- 31. Pless DD, Wellner RB (1996) In vitro fusion of endocytic vesicles: effects of reagents that alter endosomal pH. J Cell Biochem 62: 27–39.
- 32. Perez AP, Cosaka ML, Romero EL, Morilla MJ (2011) Uptake and intracellular traffic of siRNA dendriplexes in glioblastoma cells and macrophages. Int J Nanomedicine 6: 2715–2728.
- 33. Deleault NR, Kascsak R, Geoghegan JC, Supattapone S (2010) Species-dependent differences in cofactor utilization for formation of the protease-resistant prion protein in vitro. Biochemistry (Mosc) 49: 3928–3934.
- 34. Solassol J, Crozet C, Perrier V, Leclaire J, Beranger F, et al. (2004) Cationic phosphorus-containing dendrimers reduce prion replication both in cell culture and in mice infected with scrapie. J Gen Virol 85: 1791–1799.
- 35. Heegaard PMH, Pedersen HG, Flink J, Boas U (2004) Amyloid aggregates of the prion peptide PrP106-126 are destabilised by oxidation and by the action of dendrimers. FEBS Lett 577: 127–133.
- 36. Klajnert B, Cladera J, Bryszewska M (2006) Molecular interactions of dendrimers with amyloid peptides: pH dependence. Biomacromolecules 7: 2186–2191.
- 37. Klajnert B, Cortijo-Arellano M, Bryszewska M, Cladera J (2006) Influence of heparin and dendrimers on the aggregation of two amyloid peptides related to Alzheimer's and prion diseases. Biochem Biophys Res Commun 339: 577–582.
- 38. Klajnert B, Cangiotti M, Calici S, Majoral JP, Caminade AM, et al. (2007) EPR Study of the Interactions between Dendrimers and Peptides Involved in Alzheimer's and Prion Diseases. Macromolecular bioscience 7: 1065–1074.
- 39. Klajnert B, Cortijo-Arellano M, Cladera J, Majoral JP, Caminade AM, et al. (2007) Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185–208. Biochem Biophys Res Commun 364: 20–25.
- 40. Heegaard P, Boas U, Otzen D (2007) Dendrimer effects on peptide and protein fibrillation. Macromolecular bioscience 7: 1047–1059.
- 41. Masel J, Jansen VA (2000) Designing drugs to stop the formation of prion aggregates and other amyloids. Biophys Chem 88: 47–59.
- 42. Klajnert B, Cortijo-Arellano M, Cladera J, Bryszewska M (2006) Influence of dendrimer's structure on its activity against amyloid fibril formation. Biochem Biophys Res Commun 345: 21–28.